ImmuPharma plc (LON:IMM – Get Free Report) shares rose 21.4% on Monday . The stock traded as high as GBX 4.95 ($0.06) and last traded at GBX 4.78 ($0.06). Approximately 22,028,340 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 19,813,568 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Price Performance
The firm has a market cap of £18.78 million, a P/E ratio of -451.00 and a beta of 1.53. The firm has a fifty day simple moving average of GBX 1.75 and a 200-day simple moving average of GBX 1.73.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- New Year, New Buybacks: 3 Big-Name Stocks Planning Repurchases
- Trading Halts Explained
- Why These 3 Stocks With High Call Option Volume Deserve Attention
- What Do S&P 500 Stocks Tell Investors About the Market?
- D-Wave: Recent Updates Propel Shares Off 2025 Lows
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
